About Beaubrain
OUR STORY
BeauBrain Healthcare envisions a world where all people can be free from the obscure fear of dementia. We are currently working on developing an artificial intelligence (AI) program to predict ATN biomarkers for early diagnosis of dementia, as well as DTx for preventing and treating dementia. Additionally, we are making efforts to create a platform for brain health management. Our ultimate goal is to become a leading company in the realization of precision medicine for dementia.
Characteristics of Alzheimer’s Dementia
Alzheimer’s dementia, which accounts for 70% of dementia cases, is a disease that can be prevented or delayed by early diagnosis as the accumulation of Amyloid Beta, Tau, Neurodegeneration (ATN) lesions in the brain begins approximately 10 years before the onset. Under the current clinical practice guideline, if a patient visits a hospital due to cognitive decline and is diagnosed with dementia, the patient can be considered to have already developed brain atrophy.
About Beaubrain
OUR FOUNDERS
BeauBrain Healthcare was founded by world-renowned scientists and neurologists Dr. Na (Duk Ryul) and Dr. Seo (Sang Won) from Samsung Medical Center, in collaboration with Mint Venture Partners, a biotech and healthcare specialized global company builder.
Scientific Co-Founders
Sang Won Seo, MD, Ph.D
Chief Executive Officer
Scientific Co-Founders
Duk Ryul Na, MD, Ph.D
Chief Medical Officer
Company Builder
MInt Venture Partners
Company Builder
Jae-Hoon Song, MD, Ph.D
Chairman of the Board
About Beaubrain
OUR STRENGTH
For any disease, prevention is more important than treatment. Early diagnose of dementia is the starting point for the best treatment and successful prevention. BeauBrain solutions encompassing all types of dementia are built on differentiated technical skills and abundant high-quality data. The global networks and verified clinical data possessed by BeauBrain Healthcare enable us to advance into the global market early, beyond the local market.
Differentiated technical skills
- Predicting beta-amyloid positivity using MRI/CT scans only
- Reading highly versatile and compatible AI images
- Ensuring the reliability and accuracy of data (AUC of up to 0.95)
- Enabling continuous technology and product development in collaboration with Samsung Medical Center
Rapid market penetration
- Possessing multiple product pipelines already proven and utilized in clinical settings
- Having an efficient investment attraction strategy and efficient organizational structure
- Providing not only diagnostic aids but also novel values, such as predicting Amyloid, Tau, Neurodegeneration (ATN) or enabling preemptive reimbursement listing for new health technology based on prognosis prediction
High-quality data and evidence
- Amyloid PET and CT data obtained from at least 7,000 individuals
- MRI and CT data obtained from at least 30,000 individuals
- Genomic data obtained from at least 30,000 individuals
- Cognitive function findings and patient data obtained in clinical settings
Diverse Expertise & Global Network
- Prominent neurologists specializing in Alzheimer’s disease
- Healthcare, business strategy, AI/IT specialists on board
- Mint Venture Partners’ global medical networks
About Beaubrain
OUR PARTNERS
“Advancements in the healthcare and medical fields can be accomplished through the commercialization of innovative achievements by scientists and medical scientists, facilitated by forward-looking entrepreneurs. BeauBrain Healthcare is a company founded on the progressive research achievements of both internal and external leading medical scientists in the field of dementia with great unmet medical needs. In the era of aging, I aim to contribute to the growth of a locally-based startup specializing in dementia and its transformation into a global leader in the same field.”
– Jae-Hoon Song, MD, Ph.D.-
<Profile>
- Chairman & CEO, Mint Venture Partners
- Chairman & CEO, CHA Bio Group
- President, Samsung Medical Center
- Dean, Sungkyunkwan University School of Medicine
- Medical School: Seoul National University College of Medicine
“I have devoted my entire life to studying dementia as a doctor. Dementia is undeniably a distressing and heartbreaking condition for both patients and their families. Over the last three decades as a neurologist, I have been treated a multitude of patients with dementia in clinical settings. During this time, I have keenly recognized the significance of preventing dementia in daily life and have dedicated myself to extensive research and development efforts in this field. To bring my research and development projects, undertaken thus far, to fruition, I established and joined BeauBrain Healthcare. I would like to contribute to BeauBrain Healthcare’s goal as a pioneer in preventing and treating dementia during the second act of my life.”
– Duk L. Na, MD, Ph.D., Co-founder & CMO –
<Profile>
- Professor, Department of neurology, Samsung Medical Center
- Chairman, Korean Dementia Association
- Yoon Gwang-Yeol Award for Medicine from the Korean Academy of Medical Sciences
- Prime Minister’s Commendation Award
- Medical School: Seoul National University College of Medicine
“When it comes to dementia, early diagnosis is as important as prevention. If this disease is not detected early, prevention becomes less effective. As a neurologist, I have committed myself to various research and technological developments that enable the effective diagnosis and prediction of dementia, especially Alzheimer’s disease, at an early stage. With a profound sense of mission, I resolved to launch a business to ensure that these technologies could evolve into essential solutions in a clinical setting through their successful commercialization. Ultimately, my goal is to realize precision medicine for dementia based on a fusion of technology and treatment.”
– Sang Won Seo, MD, Ph.D., Co-founder & CEO –
<Profile>
- Professor, Department of neurology, Samsung Medical Center
- Training Director, Korean Dementia Association
- Presidential Commendation Award on Alzheimer’s Day
- Ministerial Commendation Award from the Ministry of Health and Welfare and the Ministry of Education
- Medical School: Yonsei University College of Medicine
Samsung Medical Center
– Founded by Samsung Medical Center/Sungkyunkwan University Faculty
– Joint research project
– Consulting and conducting clinical trials
InfoBank
- Acting as a TIPS operator.
- Received fast track designation in July 2022.
- Serving as a mentor and providing support for commercialization and investment attraction.
Daewoong Pharmaceutical
- Investing in seed rounds for startups.
- Being involved in licensing, transfers, marketing/co-marketing, or sales.